|
1.
|
Rerolle JP, Hertig A, Nguyen G, Sraer JD
and Rondeau EP: Plasminogen activator inhibitor type 1 is a
potential target in renal fibrogenesis. Kidney Int. 58:1841–1850.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Stetler-Stevenson WG: Dynamics of matrix
turnover during pathologic remodeling of the extracellular matrix.
Am J Pathol. 148:1345–1350. 1996.PubMed/NCBI
|
|
3.
|
Kruithof EK, Tran-Thang C, Ransijn A and
Bachmann F: Demonstration of a fast-acting inhibitor of plasminogen
activators in human plasma. Blood. 64:907–913. 1984.PubMed/NCBI
|
|
4.
|
Ginsburg D, Zeheb R, Yang AY, et al: cDNA
cloning of human plasminogen activator-inhibitor from endothelial
cells. J Clin Invest. 78:1673–1680. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Ny T, Sawdey M, Lawrence D, Millan JL and
Loskutoff DJ: Cloning and sequence of a cDNA coding for the human
beta-migrating endothelial-cell-type plasminogen activator
inhibitor. Proc Natl Acad Sci USA. 83:6776–6780. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Hamano K, Iwano M, Akai Y, et al:
Expression of glomerular plasminogen activator inhibitor type 1 in
glomerulonephritis. Am J Kidney Dis. 39:695–705. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kitching AR, Kong YZ, Huang XR, et al:
Plasminogen activator inhibitor-1 is a significant determinant of
renal injury in experimental crescentic glomerulonephritis. J Am
Soc Nephrol. 14:1487–1495. 2003. View Article : Google Scholar
|
|
8.
|
Yamamoto T, Noble NA, Cohen AH, et al:
Expression of transforming growth factor-beta isoforms in human
glomerular diseases. Kidney Int. 49:461–469. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Henry M, Chomiki N, Scarabin PY, et al:
Five frequent polymorphisms of the PAI-1 gene: lack of association
between genotypes, PAI activity, and triglyceride levels in a
healthy population. Arterioscler Thromb Vasc Biol. 17:851–858.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Suzuki H, Sakuma Y, Kanesaki Y, et al:
Close relationship of plasminogen activator inhibitor-1 4G/5G
polymorphism and progression of IgA nephropathy. Clin Nephrol.
62:173–179. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ding R, Chen XM, Liu SW, Lv Y and Wu J:
Relationship between PAI-1 gene 4G/5G polymorphism and clinical
profile of IgA nephropathy. Zhonghua Yi Xue Yi Chuan Xue Za Zhi.
23:449–451. 2006.(In Chinese).
|
|
12.
|
Chen CH, Shu KH, Wen MC, et al: Impact of
plasminogen activator inhibitor-1 gene polymorphisms on primary
membranous nephropathy. Nephrol Dial Transplant. 23:3166–3173.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Wang AY, Poon P, Lai FM, et al:
Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype
and lupus nephritis in Chinese patients. Kidney Int. 59:1520–1528.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Wong TY, Poon P, Szeto CC, Chan JC and Li
PK: Association of plasminogen activator inhibitor-1 4G/4G genotype
and type 2 diabetic nephropathy in Chinese patients. Kidney Int.
57:632–638. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Cho BS, Kim SD, Choi YM and Kang HH:
School urinalysis screening in Korea: prevalence of chronic renal
disease. Pediatr Nephrol. 16:1126–1128. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Floege J and Feehally J: IgA nephropathy:
recent developments. J Am Soc Nephrol. 11:2395–2403.
2000.PubMed/NCBI
|
|
17.
|
Utsunomiya Y, Koda T, Kado T, et al:
Incidence of pediatric IgA nephropathy. Pediatr Nephrol.
18:511–515. 2003.PubMed/NCBI
|
|
18.
|
Feehally J: IgA nephropathy and
Henoch-Schönlein nephritis. Comprehensive Clinical Nephrology.
Johnson RJ and Feehally J: Mosby; London: pp. 2–7. 2000, PubMed/NCBI
|
|
19.
|
Packham D: Prognosis in IgA nephropathy.
Nephrol Dial Transplant. 3:231–235. 1997.
|
|
20.
|
Kimura H, Gejyo F, Suzuki Y, et al:
Polymorphisms of angiotensin converting enzyme and plasminogen
activator inhibitor-1 genes in diabetes and macroangiopathy1.
Kidney Int. 54:1659–1669. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Gardemann A, Lohre J, Katz N, et al: The
4G4G genotype of the plasminogen activator inhibitor 4G/5G gene
polymorphism is associated with coronary atherosclerosis in
patients at high risk for this disease. Thromb Haemost.
82:1121–1126. 1999.PubMed/NCBI
|
|
22.
|
Grubic N, Stegnar M, Peternel P, Kaider A
and Binder BR: A novel G/A and the 4G/5G polymorphism within the
promoter of the plasminogen activator inhibitor-1 gene in patients
with deep vein thrombosis. Thromb Res. 84:431–443. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Song J, Yoon YM, Jung HJ, et al:
Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and
coagulation factor VII Arg353-->Gln polymorphism in Korean
patients with coronary artery disease. J Korean Med Sci.
15:146–152. 2000.PubMed/NCBI
|
|
24.
|
Eriksson P, Kallin B, van’t Hooft FM,
Bavenholm P and Hamsten A: Allele-specific increase in basal
transcription of the plasminogen-activator inhibitor 1 gene is
associated with myocardial infarction. Proc Natl Acad Sci USA.
92:1851–1855. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Wyatt RJ, Kritchevsky SB, Woodford SY, et
al: IgA nephropathy: long-term prognosis for pediatric patients. J
Pediatr. 127:913–919. 1995. View Article : Google Scholar : PubMed/NCBI
|
